Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Sanai Health Industry Group Co's Revenue for the
six
months ended in Dec. 2025 was €4.69 Mil. Sanai Health Industry Group Co's average Accounts Receivable for the
six
months ended in Dec. 2025 was €0.74 Mil.
Hence, Sanai Health Industry Group Co's Receivables Turnover for the
six
months ended in Dec. 2025 was 6.35.
Sanai Health Industry Group Co (FRA:WUP0) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Sanai Health Industry Group Co Receivables Turnover Related Terms
Sanai Health Industry Group Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanai Health Industry Group Co Receivables Turnover Chart
FRA:WUP0 vs ZTS, UTHR, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sanai Health Industry Group Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanai Health Industry Group Co Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanai Health Industry Group Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Sanai Health Industry Group Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanai Health Industry Group Co (FRA:WUP0) has a Receivables Turnover of 6.35 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sanai Health Industry Group Co and its competitors. According to the industry distribution chart, Sanai Health Industry Group Co ranks #99 out of 950 companies in the Drug Manufacturers industry, placing it in the top 10.4%.
Is Sanai Health Industry Group Co's Receivables Turnover too high?
Sanai Health Industry Group Co's current Receivables Turnover is 6.35. The Drug Manufacturers industry median Receivables Turnover is 5.07. Sanai Health Industry Group Co's value of 6.35 is 25.4% above this industry median. Based on the distribution chart, Sanai Health Industry Group Co ranks #99 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanai Health Industry Group Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Sanai Health Industry Group Co's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sanai Health Industry Group Co ranks #99 out of 950 companies for Receivables Turnover. This places Sanai Health Industry Group Co in the top 10% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. Sanai Health Industry Group Co's value of 6.35 is 25.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanai Health Industry Group Co's current Receivables Turnover of 6.35 is 25.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sanai Health Industry Group Co and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanai Health Industry Group Co's current Receivables Turnover is 6.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanai Health Industry Group Co stock overvalued right now?
Sanai Health Industry Group Co (FRA:WUP0) has a current Receivables Turnover of 6.35. The stock's GF Value™ is €0.07, compared to a current price of €0.03 — trading 64.3% below its estimated fair value. The current Receivables Turnover is 6.35 and 25.4% above the Drug Manufacturers industry median of 5.07. Sanai Health Industry Group Co's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Sanai Health Industry Group Co (FRA:WUP0), the current Receivables Turnover is 6.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanai Health Industry Group Co (FRA:WUP0) Overvalued in 2026?
Based on GuruFocus' analysis, Sanai Health Industry Group Co stock appears to be undervalued.
The current stock price of €0.03 is trading 64.3% below its estimated GF Value™ of €0.07.
Key valuation signals for FRA:WUP0:
Receivables Turnover: 6.35
GF Value™: €0.07 vs. price of €0.03 (64.3% below fair value)
Industry Position: 25.4% above the Drug Manufacturers median (#99 of 950)
No single metric tells the full story. See the FRA:WUP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanai Health Industry Group Co Business Description
Sanai Health Industry Group Co Ltd is a pharmaceutical company. The company has three reportable segments namely Pharmaceutical products include development, manufacturing, marketing, and sales of pharmaceutical products and related software and provision of consultancy services. Finance leasing includes the provision of financial leasing services; Genetic testing and molecular diagnostic services segment. It generates maximum revenue from Pharmaceutical products segments. Geographically, it derives the majority of its revenue from the PRC.
38GF Score
Get the complete analysis for FRA:WUP0
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:WUP0 has been successfully added to your 
